Comparative Pharmacology
Head-to-head clinical analysis: PROVAL 3 versus TESSALON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROVAL 3 versus TESSALON.
PROVAL #3 vs TESSALON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proval #3 is a combination of acetaminophen (paracetamol), butalbital, and caffeine. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis in the CNS, raising the pain threshold. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation and anxiolysis. Caffeine is a CNS stimulant that potentiates analgesic effects via adenosine receptor antagonism.
Benzonatate is a local anesthetic structurally related to tetracaine that inhibits pulmonary stretch receptors and reduces the cough reflex by decreasing the sensitivity of vagal afferent fibers in the respiratory tract.
1-2 tablets orally every 4-6 hours as needed for pain; not to exceed 8 tablets per day.
100 mg orally three times daily as needed for cough. Maximum 600 mg/day.
None Documented
None Documented
4–6 hours in adults with normal hepatic function; prolonged in hepatic impairment (8–12 hours).
Terminal elimination half-life is approximately 12-15 hours in adults; significant interindividual variability. No accumulation with q6h dosing.
Primarily hepatic metabolism (CYP450) with <5% excreted unchanged in urine. Biliary/fecal elimination accounts for ~15% as metabolites.
Renal: <5% unchanged; primary route is hepatic metabolism with metabolites excreted renally and fecally; exact biliary/fecal % not established in humans.
Category C
Category C
Antitussive
Antitussive